A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
← catalyst calendarNCT07215234 · readout in 419 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
104estimated
Sites
18
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-09 | actual | When the study began enrolling |
| Primary completion | 2027-10-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-07-22 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Geographic Atrophy
Interventions
- Drug: SAR446597
- Drug: Sham Comparator
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs)
measured Day 1 to Week 104
Incidence and severity of ocular and non-ocular treatment-emergent serious adverse events (TESAEs)
measured Day 1 to Week 104
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed